Vigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Significant Drop in Short Interest

Vigil Neuroscience, Inc. (NASDAQ:VIGL) saw a significant decline in short interest in September. As of September 15th, there was short interest totalling 546,600 shares, a decline of 20.3% from the August 31st total of 685,800 shares. Currently, 2.7% of the shares of the company are short sold. Based on an average daily trading volume, of 488,600 shares, the short-interest ratio is currently 1.1 days.

Institutional Investors Weigh In On Vigil Neuroscience

Large investors have recently modified their holdings of the business. Acadian Asset Management LLC acquired a new position in Vigil Neuroscience during the second quarter worth about $26,000. Renaissance Technologies LLC lifted its stake in Vigil Neuroscience by 19.2% in the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock worth $286,000 after purchasing an additional 11,536 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Vigil Neuroscience during the 2nd quarter worth approximately $87,000. Vanguard Group Inc. increased its holdings in shares of Vigil Neuroscience by 11.9% in the first quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock valued at $3,050,000 after purchasing an additional 95,276 shares during the last quarter. Finally, Ensign Peak Advisors Inc lifted its position in Vigil Neuroscience by 72.8% during the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock worth $1,580,000 after buying an additional 166,442 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Vigil Neuroscience Price Performance

Vigil Neuroscience stock traded up $0.03 during midday trading on Friday, reaching $3.30. The company had a trading volume of 1,406 shares, compared to its average volume of 259,308. Vigil Neuroscience has a 12-month low of $2.47 and a 12-month high of $9.24. The firm’s fifty day simple moving average is $3.61 and its 200-day simple moving average is $3.52. The company has a market capitalization of $130.85 million, a P/E ratio of -1.54 and a beta of 1.96.

Vigil Neuroscience (NASDAQ:VIGL) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.02. On average, analysts expect that Vigil Neuroscience will post -2.15 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $17.00 target price on shares of Vigil Neuroscience in a research note on Wednesday, August 14th. Wedbush reiterated an “outperform” rating and set a $23.00 price target on shares of Vigil Neuroscience in a research report on Thursday, July 11th. Finally, Guggenheim cut their price objective on Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $16.60.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.